Innovation in Central Venous Access Device Security: A Pilot Randomized Controlled Trial in Pediatric Critical Care. Ullman, A. J, Long, D., Williams, T., Pearson, K., Mihala, G., Mattke, A. C, Macfarlane, F., & Rickard, C. M Pediatric Critical Care Medicine, 20(10):e480–e488, July, 2019.
Paper doi abstract bibtex Objectives: Central venous access devices enable many treatments during critical illness; however, 25% of pediatric central venous access devices fail before completion of treatment due to infection, thrombosis, dislodgement, and occlusion. This is frequently attributed to inadequate securement and dressing of the device; however, high-quality research evaluating pediatric central venous access device securement innovation to prevent central venous access device failure is scarce. This study aimed to establish the feasibility of a definitive randomized control trial examining the effectiveness of current and new technologies to secure central venous access devices in pediatrics. Design: Single-center, parallel group, superiority, pilot randomized control trial. Setting: Anesthetic and intensive care departments of a tertiary pediatric hospital Subjects: One-hundred eighty pediatric patients with nontunneled central venous access device Interventions: Participants were randomized to receive central venous access device securement via standard care (bordered polyurethane dressing, with prolene sutures, chlorhexidine gluconate disc), tissue adhesive (Histoacryl, B Braun, Melsungen, Germany) in addition to standard care; or integrated dressing securement (SorbaView SHIELD [Centurion Medical Products, Franklin, MA], with prolene sutures and chlorhexidine gluconate disc). Outcomes: Primary: Feasibility (including effect size estimates, acceptability); central venous access device failure; central venous access device complications; secondary: individual central venous access device complications, skin damage, dressing performance, and product cost. Measurements and Main Results: Feasibility criteria were achieved as recruitment occurred with acceptable eligibility, recruitment, missing data, and attrition rates, as well as good protocol adherence. Family members and staff-reported comparable levels of acceptability between study arms; however, tissue adhesive was reported as the most difficult to apply. Overall, 6% of central venous access devices failed, including 6% (3/54; incident rate, 13.2 per 1,000 catheter days) standard care, 2% (1/56; incident rate, 3.65 per 1,000 catheter days) integrated, and 8% (5/59; 25.0 per 1,000 catheter days) tissue adhesive. Conclusions: It is feasible to conduct an efficacy randomized control trial of the studied interventions. Further research is required to definitively identify clinical, cost-effective methods to prevent central venous access device failure by examining new dressing and securement technologies and techniques.
@article{ullman_innovation_2019,
title = {Innovation in {Central} {Venous} {Access} {Device} {Security}: {A} {Pilot} {Randomized} {Controlled} {Trial} in {Pediatric} {Critical} {Care}},
volume = {20},
issn = {1529-7535},
url = {http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=31274778&retmode=ref&cmd=prlinks},
doi = {10.1097/pcc.0000000000002059},
abstract = {Objectives: Central venous access devices enable many treatments during critical illness; however, 25\% of pediatric central venous access devices fail before completion of treatment due to infection, thrombosis, dislodgement, and occlusion. This is frequently attributed to inadequate securement and dressing of the device; however, high-quality research evaluating pediatric central venous access device securement innovation to prevent central venous access device failure is scarce. This study aimed to establish the feasibility of a definitive randomized control trial examining the effectiveness of current and new technologies to secure central venous access devices in pediatrics. Design: Single-center, parallel group, superiority, pilot randomized control trial. Setting: Anesthetic and intensive care departments of a tertiary pediatric hospital Subjects: One-hundred eighty pediatric patients with nontunneled central venous access device Interventions: Participants were randomized to receive central venous access device securement via standard care (bordered polyurethane dressing, with prolene sutures, chlorhexidine gluconate disc), tissue adhesive (Histoacryl, B Braun, Melsungen, Germany) in addition to standard care; or integrated dressing securement (SorbaView SHIELD [Centurion Medical Products, Franklin, MA], with prolene sutures and chlorhexidine gluconate disc). Outcomes: Primary: Feasibility (including effect size estimates, acceptability); central venous access device failure; central venous access device complications; secondary: individual central venous access device complications, skin damage, dressing performance, and product cost. Measurements and Main Results: Feasibility criteria were achieved as recruitment occurred with acceptable eligibility, recruitment, missing data, and attrition rates, as well as good protocol adherence. Family members and staff-reported comparable levels of acceptability between study arms; however, tissue adhesive was reported as the most difficult to apply. Overall, 6\% of central venous access devices failed, including 6\% (3/54; incident rate, 13.2 per 1,000 catheter days) standard care, 2\% (1/56; incident rate, 3.65 per 1,000 catheter days) integrated, and 8\% (5/59; 25.0 per 1,000 catheter days) tissue adhesive. Conclusions: It is feasible to conduct an efficacy randomized control trial of the studied interventions. Further research is required to definitively identify clinical, cost-effective methods to prevent central venous access device failure by examining new dressing and securement technologies and techniques.},
number = {10},
journal = {Pediatric Critical Care Medicine},
author = {Ullman, Amanda J and Long, Debbie and Williams, Tara and Pearson, Kylie and Mihala, Gabor and Mattke, Adrian C and Macfarlane, Fiona and Rickard, Claire M},
month = jul,
year = {2019},
pages = {e480--e488},
}
Downloads: 0
{"_id":"29SHqs9LFBncA5DJ6","bibbaseid":"ullman-long-williams-pearson-mihala-mattke-macfarlane-rickard-innovationincentralvenousaccessdevicesecurityapilotrandomizedcontrolledtrialinpediatriccriticalcare-2019","authorIDs":[],"author_short":["Ullman, A. J","Long, D.","Williams, T.","Pearson, K.","Mihala, G.","Mattke, A. C","Macfarlane, F.","Rickard, C. M"],"bibdata":{"bibtype":"article","type":"article","title":"Innovation in Central Venous Access Device Security: A Pilot Randomized Controlled Trial in Pediatric Critical Care","volume":"20","issn":"1529-7535","url":"http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=31274778&retmode=ref&cmd=prlinks","doi":"10.1097/pcc.0000000000002059","abstract":"Objectives: Central venous access devices enable many treatments during critical illness; however, 25% of pediatric central venous access devices fail before completion of treatment due to infection, thrombosis, dislodgement, and occlusion. This is frequently attributed to inadequate securement and dressing of the device; however, high-quality research evaluating pediatric central venous access device securement innovation to prevent central venous access device failure is scarce. This study aimed to establish the feasibility of a definitive randomized control trial examining the effectiveness of current and new technologies to secure central venous access devices in pediatrics. Design: Single-center, parallel group, superiority, pilot randomized control trial. Setting: Anesthetic and intensive care departments of a tertiary pediatric hospital Subjects: One-hundred eighty pediatric patients with nontunneled central venous access device Interventions: Participants were randomized to receive central venous access device securement via standard care (bordered polyurethane dressing, with prolene sutures, chlorhexidine gluconate disc), tissue adhesive (Histoacryl, B Braun, Melsungen, Germany) in addition to standard care; or integrated dressing securement (SorbaView SHIELD [Centurion Medical Products, Franklin, MA], with prolene sutures and chlorhexidine gluconate disc). Outcomes: Primary: Feasibility (including effect size estimates, acceptability); central venous access device failure; central venous access device complications; secondary: individual central venous access device complications, skin damage, dressing performance, and product cost. Measurements and Main Results: Feasibility criteria were achieved as recruitment occurred with acceptable eligibility, recruitment, missing data, and attrition rates, as well as good protocol adherence. Family members and staff-reported comparable levels of acceptability between study arms; however, tissue adhesive was reported as the most difficult to apply. Overall, 6% of central venous access devices failed, including 6% (3/54; incident rate, 13.2 per 1,000 catheter days) standard care, 2% (1/56; incident rate, 3.65 per 1,000 catheter days) integrated, and 8% (5/59; 25.0 per 1,000 catheter days) tissue adhesive. Conclusions: It is feasible to conduct an efficacy randomized control trial of the studied interventions. Further research is required to definitively identify clinical, cost-effective methods to prevent central venous access device failure by examining new dressing and securement technologies and techniques.","number":"10","journal":"Pediatric Critical Care Medicine","author":[{"propositions":[],"lastnames":["Ullman"],"firstnames":["Amanda","J"],"suffixes":[]},{"propositions":[],"lastnames":["Long"],"firstnames":["Debbie"],"suffixes":[]},{"propositions":[],"lastnames":["Williams"],"firstnames":["Tara"],"suffixes":[]},{"propositions":[],"lastnames":["Pearson"],"firstnames":["Kylie"],"suffixes":[]},{"propositions":[],"lastnames":["Mihala"],"firstnames":["Gabor"],"suffixes":[]},{"propositions":[],"lastnames":["Mattke"],"firstnames":["Adrian","C"],"suffixes":[]},{"propositions":[],"lastnames":["Macfarlane"],"firstnames":["Fiona"],"suffixes":[]},{"propositions":[],"lastnames":["Rickard"],"firstnames":["Claire","M"],"suffixes":[]}],"month":"July","year":"2019","pages":"e480–e488","bibtex":"@article{ullman_innovation_2019,\n\ttitle = {Innovation in {Central} {Venous} {Access} {Device} {Security}: {A} {Pilot} {Randomized} {Controlled} {Trial} in {Pediatric} {Critical} {Care}},\n\tvolume = {20},\n\tissn = {1529-7535},\n\turl = {http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=31274778&retmode=ref&cmd=prlinks},\n\tdoi = {10.1097/pcc.0000000000002059},\n\tabstract = {Objectives: Central venous access devices enable many treatments during critical illness; however, 25\\% of pediatric central venous access devices fail before completion of treatment due to infection, thrombosis, dislodgement, and occlusion. This is frequently attributed to inadequate securement and dressing of the device; however, high-quality research evaluating pediatric central venous access device securement innovation to prevent central venous access device failure is scarce. This study aimed to establish the feasibility of a definitive randomized control trial examining the effectiveness of current and new technologies to secure central venous access devices in pediatrics. Design: Single-center, parallel group, superiority, pilot randomized control trial. Setting: Anesthetic and intensive care departments of a tertiary pediatric hospital Subjects: One-hundred eighty pediatric patients with nontunneled central venous access device Interventions: Participants were randomized to receive central venous access device securement via standard care (bordered polyurethane dressing, with prolene sutures, chlorhexidine gluconate disc), tissue adhesive (Histoacryl, B Braun, Melsungen, Germany) in addition to standard care; or integrated dressing securement (SorbaView SHIELD [Centurion Medical Products, Franklin, MA], with prolene sutures and chlorhexidine gluconate disc). Outcomes: Primary: Feasibility (including effect size estimates, acceptability); central venous access device failure; central venous access device complications; secondary: individual central venous access device complications, skin damage, dressing performance, and product cost. Measurements and Main Results: Feasibility criteria were achieved as recruitment occurred with acceptable eligibility, recruitment, missing data, and attrition rates, as well as good protocol adherence. Family members and staff-reported comparable levels of acceptability between study arms; however, tissue adhesive was reported as the most difficult to apply. Overall, 6\\% of central venous access devices failed, including 6\\% (3/54; incident rate, 13.2 per 1,000 catheter days) standard care, 2\\% (1/56; incident rate, 3.65 per 1,000 catheter days) integrated, and 8\\% (5/59; 25.0 per 1,000 catheter days) tissue adhesive. Conclusions: It is feasible to conduct an efficacy randomized control trial of the studied interventions. Further research is required to definitively identify clinical, cost-effective methods to prevent central venous access device failure by examining new dressing and securement technologies and techniques.},\n\tnumber = {10},\n\tjournal = {Pediatric Critical Care Medicine},\n\tauthor = {Ullman, Amanda J and Long, Debbie and Williams, Tara and Pearson, Kylie and Mihala, Gabor and Mattke, Adrian C and Macfarlane, Fiona and Rickard, Claire M},\n\tmonth = jul,\n\tyear = {2019},\n\tpages = {e480--e488},\n}\n\n\n\n","author_short":["Ullman, A. J","Long, D.","Williams, T.","Pearson, K.","Mihala, G.","Mattke, A. C","Macfarlane, F.","Rickard, C. M"],"key":"ullman_innovation_2019","id":"ullman_innovation_2019","bibbaseid":"ullman-long-williams-pearson-mihala-mattke-macfarlane-rickard-innovationincentralvenousaccessdevicesecurityapilotrandomizedcontrolledtrialinpediatriccriticalcare-2019","role":"author","urls":{"Paper":"http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=31274778&retmode=ref&cmd=prlinks"},"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"http://bibbase.org/zotero-group/gxu917/1345589","creationDate":"2020-02-28T10:11:11.384Z","downloads":0,"keywords":[],"search_terms":["innovation","central","venous","access","device","security","pilot","randomized","controlled","trial","pediatric","critical","care","ullman","long","williams","pearson","mihala","mattke","macfarlane","rickard"],"title":"Innovation in Central Venous Access Device Security: A Pilot Randomized Controlled Trial in Pediatric Critical Care","year":2019,"dataSources":["4P4hKw3sZj97Zz2kx"]}